Targeted Restoration of the Intestinal Microbiota with a Simple, Defined Bacteriotherapy Resolves Relapsing Clostridium difficile Disease in Mice
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Relapsing C. difficile disease in humans is linked to a pathological imbalance within the intestinal microbiota, termed dysbiosis, which remains poorly understood. We show that mice infected with epidemic C. difficile (genotype 027/BI) develop highly contagious, chronic intestinal disease and persistent dysbiosis characterized by a distinct, simplified microbiota containing opportunistic pathogens and altered metabolite production. Chronic C. difficile 027/BI infection was refractory to vancomycin treatment leading to relapsing disease. In contrast, treatment of C. difficile 027/BI infected mice with feces from healthy mice rapidly restored a diverse, healthy microbiota and resolved C. difficile disease and contagiousness. We used this model to identify a simple mixture of six phylogenetically diverse intestinal bacteria, including novel species, which can re-establish a health-associated microbiota and clear C. difficile 027/BI infection from mice. Thus, targeting a dysbiotic microbiota with a defined mixture of phylogenetically diverse bacteria can trigger major shifts in the microbial community structure that displaces C. difficile and, as a result, resolves disease and contagiousness. Further, we demonstrate a rational approach to harness the therapeutic potential of health-associated microbial communities to treat C. difficile disease and potentially other forms of intestinal dysbiosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Whole genome (maximum likelihood) phylogeny of intestinal bacteria demonstrating the phylogenetic placement of disease-resolving bacteriotherapy bacteria (MixB) and the dominant members of the supershedder microbiota. Maximum likelihood phylogeny produced using FastTree from the concatenated protein sequence of 44 common genes (See methods). Species names marked in green indicate members of the suppressive MixB mixture, names marked in red indicate species that were commonly detected in the feces of supershedding mice, names in black are reference genomes from common intestinal bacteria that were included to provide phylogenetic context to the tree. Taxonomic designations are given at the relevant branch nodes. Adjacent pictures are transmission electron micrographs of sectioned bacterial strains that constitute MixB. Methods for sample processing and imaging have been described [33]. Scale bars are shown below bacteria.](https://figures.cochat.ai/paper-figures/d26cd52a622e48fbb6e5369ce372b754/targeted-restoration-of-the-intestinal-microbiota-with-a-simple-defined-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Decrease in Lachnospiraceae has been associated with severe CDI suggesting a protective role for members of this family51”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [51]
Experimental — accuracy not yet measuredIn the citing paper
“Bacterial strains [54, 118, 119] and metabolites [54] associated with protection from C. difficile have now been identified”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894
Velvet: Algorithms for de novo short read assembly using de Bruijn graphs
Zerbino, D. R., & Birney, E. (2008) · Genome Research · doi:10.1101/gr.074492.107 · Cited by 9,491
ARB: a software environment for sequence data
Ludwig, W. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh293 · Cited by 6,702
The Ribosomal Database Project: improved alignments and new tools for rRNA analysis
Cole, J. R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R. J., Kulam-Syed-Mohideen, A. S., McGarrell, D. M., Marsh, T., Garrity, G. M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn879 · Cited by 4,762
Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation
Letunic, I., & Bork, P. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btl529 · Cited by 3,299
Identifying bacterial genes and endosymbiont DNA with Glimmer
Delcher, A. L., Bratke, K. A., Powers, E. C., & Salzberg, S. L. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm009 · Cited by 3,134
Colonic Health: Fermentation and Short Chain Fatty Acids
Wong, J. M. W., de Souza, R., Kendall, C. W. C., Emam, A., & Jenkins, D. J. A. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200603000-00015 · Cited by 2,739
More powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715 · cited 1×
“Adjusted p-values were calculated using the Benjamini and Hochberg method [57].”
MethodSchloss, P. D., & Handelsman, J. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.3.1501-1506.2005 · Cited by 2,501
Cited by
Items 301–400 of 539
Bollinger, K. W., Müh, U., Ocius, K. L., Apostolos, A. J., Pires, M. M., Helm, R. F., Popham, D. L., Weiss, D. S., & Ellermeier, C. D. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2408540121 · Cited by 22
“These antibiotics have the unintended conse quence of disrupting the intestinal microbiota that ordinarily keeps C. difficile in check ( 2 , 3 ).”
Schmidt, C. (2013) · Nature Biotechnology · doi:10.1038/nbt.2544 · Cited by 23
Supra-organismal interactions in the human intestine
Glendinning, L., & Free, A. (2014) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2014.00047 · Cited by 25
“…patients with recurrent Clostridium difficile infection and UC (Walker and Lawley, 2013), experiments in mouse models demonstrate that it is an effective way of re-establishing a healthy microbiome in dysbiotic animals which is resistant to subsequent challenge with pathogens (Lawley et al., 2012).”
BackgroundRole of Gut-Brain Axis in the Aetiology of Neurodevelopmental Disorders with Reference to Autism
Rizk, M. Z. (2012) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.s6-005 · Cited by 24
Brandt, L. J. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000346 · Cited by 24
Methodological Strategies in Microbiome Research and their Explanatory Implications
O’Malley, M. A., & Skillings, D. (2018) · Perspectives on Science · doi:10.1162/posc_a_00274 · Cited by 30
“This work targets the precise causal agents that ameliorate C. difficile infections (e.g., Buffie et al. 2015; Lawley et al. 2012, Almeida et al. 2016).”
BackgroundFaecal transplantation for the treatment of Clostridium difficile infection: a review
McCune, V. L., Struthers, J. K., & Hawkey, P. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.10.009 · Cited by 29
New Perspectives in Clostridium difficile Disease Pathogenesis
Monaghan, T. M. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2014.11.007 · Cited by 30
Effects of Tigecycline and Vancomycin Administration on Established Clostridium difficile Infection
Theriot, C. M., Schumacher, C. A., Bassis, C. M., Seekatz, A. M., & Young, V. B. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04296-14 · Cited by 24
Pakyz, A. L., Moczygemba, L. R., VanderWielen, L. M., & Edmond, M. B. (2016) · American Journal of Infection Control · doi:10.1016/j.ajic.2016.01.018 · Cited by 24
Munoz, S., Guzmán-Rodríguez, M., Sun, J., Zhang, Y., Noordhof, C., He, S.-M., Allen‐Vercoe, E., Claud, E. C., & Petrof, E. O. (2016) · Gut Microbes · doi:10.1080/19490976.2016.1188248 · Cited by 21
“difficile infection.(45) Finally, as mentioned previously, defined probiotic mixtures such as VSL#3, which contains 8”
BackgroundMiezeiewski, M., Schnaufer, T., Muravsky, M., Wang, S., Caro-Aguilar, I., Secore, S., Thiriot, D. S., Hsu, C. C., Rogers, I. T., DeSantis, T. Z., et al. (2014) · The ISME Journal · doi:10.1038/ismej.2014.127 · Cited by 21
Incorporating functional trade-offs into studies of the gut microbiota
Reese, A. T., & Kearney, S. M. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.09.003 · Cited by 20
Causal role of the gut microbiome in certain human diseases: a narrative review
Prosty, C. J., Katergi, K., Papenburg, J., Lawandi, A., Lee, T. C., Shi, H., Burnham, P., Swem, L. R., Routy, B., Yansouni, C. P., et al. (2024) · eGastroenterology · doi:10.1136/egastro-2024-100086 · Cited by 24
“25 In total, 19 RCTs of microbiome therapies for CDI met inclusion criteria 6 7 26–42 (figure 2).”
Woloszynek, S., Pastor, S. J., Mell, J. C., Nandi, N., Sokhansanj, B. A., & ROSEN, G. L. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.01.003 · Cited by 26
Pino, R. E. H. D., Barbero, A. M., Español, L. Á., Morro, L. S., & Pasquinelli, V. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4vmr0720-201r · Cited by 25
Artificial selection of microbial communities: what have we learnt and how can we improve?
Thomas, J., Rowland-Chandler, J., & Shou, W. (2023) · Current Opinion in Microbiology · doi:10.1016/j.mib.2023.102400 · Cited by 25
“Examples include the bioindustrial synthesis of certain natural products [4,5], protection against pathogens [6], and the degradation of harmful waste compounds [7,8].”
BackgroundClavel, T., Faber, F., Groussin, M., Haller, D., Overmann, J., Pauvert, C., Poyet, M., Selkrig, J., Stecher, B., Typas, A., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02660-6 · Cited by 21
Björkqvist, O., Rangel, I., Serrander, L., Magnusson, C., Halfvarson, J., Norén, T., & Jungeström, M. B. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249861 · Cited by 20
Prevalence of Clostridioides difficile in Canine Feces and Its Association with Intestinal Dysbiosis
Werner, M., Ishii, P. E., Pilla, R., Lidbury, J. A., Steiner, J. M., Busch, K., Unterer, S., & Suchodolski, J. S. (2023) · Animals · doi:10.3390/ani13152441 · Cited by 21
Quorum Sensing and the Gut Microbiome
Jimenez, A. G., & Sperandio, V. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814905-8.00006-x · Cited by 24
Jukes, C., Ijaz, U. Z., Buckley, A. M., Spencer, J., Irvine, J. J., Candlish, D., Li, J. V., Marchesi, J. R., & Douce, G. R. (2019) · Gut Microbes · doi:10.1080/19490976.2019.1678996 · Cited by 19
“It is feasible that many of the therapeutic bacterial mixtures already contain strains expressing BSH activity.(10,15) In fact, the successful cocktail used to treat mice by Lawley et al.”
Brauer, M., Lassek, C., Hinze, C., Hoyer, J., Becher, D., Jahn, D., Sievers, S., & Riedel, K. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.682111 · Cited by 25
Clostridium difficileinfection aggravates colitis in interleukin 10-deficient mice
Kim, M. N. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i45.17084 · Cited by 20
Maltecca, C., Dunn, R. R., He, Y., McNulty, N. P., Schillebeeckx, C., Schwab, C. R., Shull, C. M., Fix, J., & Tiezzi, F. (2021) · Animal Microbiome · doi:10.1186/s42523-021-00118-z · Cited by 20
Fecal microbiota transplantation for Clostridium difficile infection: back to the future
Borgia, G., Maraolo, A. E., Foggia, M., Buonomo, A. R., & Gentile, I. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1045872 · Cited by 22
Dietary Regulation of the Gut Microbiota Engineered by a Minimal Defined Bacterial Consortium
Shen, T. D., Chehoud, C., Ni, J., Hsu, E. K., Chen, Y.-Y., Bailey, A., Laughlin, A. L., Bittinger, K. L., Bushman, F. D., & Wu, G. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155620 · Cited by 20
“The use of feces could be considered an untargeted approach with potential risks [11], but growing evidence suggests that the use of defined microbial consortia could be developed to treat disease [12, 13].”
BackgroundDiversity-Function Relationships in Natural, Applied, and Engineered Microbial Ecosystems
Free, A., McDonald, M. A., & Pagaling, E. (2018) · Advances in applied microbiology · doi:10.1016/bs.aambs.2018.07.002 · Cited by 19
“to external influences such as antibiotic usage (Buffie et al., 2012; Lawley et al., 2012) and diet (Carmody et al.”
BackgroundInfluentialHuus, K. E., Frankowski, M., Pučić‐Baković, M., Vučković, F., Lauc, G., Mullish, B. H., Marchesi, J. R., Monaghan, T. M., Kao, D. H., & Finlay, B. B. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1862027 · Cited by 19
Returning to Nature for the Next Generation of Antimicrobial Therapeutics
MacNair, C. R., Tsai, C. N., Rutherford, S. T., & Tan, M. (2023) · Antibiotics · doi:10.3390/antibiotics12081267 · Cited by 22
Re-framing the importance of Group B Streptococcus as a gut-resident pathobiont
Ling, J., & Hryckowian, A. J. (2024) · Infection and Immunity · doi:10.1128/iai.00478-23 · Cited by 16
“More recently, a phase III, double-blind, randomized, placebo-control led trial of an orally delivered probiotic consisting of Bacillota spores showed a decrease in rCDI in humans (227).”
BackgroundInfluentialFaecal microbiota transplantation: A sui generis biological drug, not a tissue
Megerlin, F., Fouassier, É., Lopert, R., & Bourlioux, P. (2014) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2014.04.008 · Cited by 19
Clostridioides difficile Infection in Chronic Kidney Disease/End-Stage Renal Disease
Ramesh, M. S., & Yee, J. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.01.001 · Cited by 18
Wittmann, A., Autenrieth, I. B., & Frick, J.-S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071338 · Cited by 18
“[37].”
A clinical primer of the role of gut microbiome in health and disease
Yang, A. L., & Kashyap, P. (2015) · Tropical Gastroenterology · doi:10.7869/tg.238 · Cited by 19
“difficile.(76) Similarly, Chen et al developed a mouse model of C.”
BackgroundLappan, R. J., & Peacock, C. S. (2019) · Microbiology Australia · doi:10.1071/ma19051 · Cited by 20
Elahi, M., Nakayama‐Imaohji, H., Hashimoto, M., Tada, A., Yamasaki, H., Nagao, T., & Kuwahara, T. (2021) · Antibiotics · doi:10.3390/antibiotics10020187 · Cited by 16
“reported that bacteriotherapy using a simple mixture of six intestinal bacteria—Staphylococcus warneri, Enterococcus hirae, Lactobacillus reuteri, as well as three novel species of Anaerostipes, Enterorhabdus, and Bacteroides—resolved CD disease and transmission in a mouse model [27].”
BackgroundThe potential of microbiome replacement therapies for Clostridium difficile infection
Buckley, A. M., Moura, I. B., & Wilcox, M. H. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000800 · Cited by 17
“difficile in a recurrent mouse model to resolve disease [42].”
BackgroundThe potential of microbiome replacement therapies for Clostridium difficile infection
Buckley, A., Moura, I., & Wilcox, M. (2022) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 16
Beyi, A. F., Wannemuehler, M. J., & Plummer, P. J. (2022) · Antibiotics · doi:10.3390/antibiotics11081093 · Cited by 19
Colenutt, C., & Cutting, S. M. (2014) · FEMS Microbiology Letters · doi:10.1111/1574-6968.12468 · Cited by 16
“More recently, ‘synthetic stools’ have been developed (Lawley et al., 2012; Petrof et al., 2013), selecting particular microorganisms that are able to resolve infections through rebuilding the microbial communities in the gut without the unpleasant and uncertain aspect of faecal transplants.”
BackgroundRahman, M. U., Shah, J. A., Khan, M. N., Bilal, H., Zhu, D., Du, Z., & Mu, D. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10676-2 · Cited by 23
Curtis, T., Daran, J.-M. G., Pronk, J. T., Frey, J., Jansson, J. K., Robbins‐Pianka, A., Knight, R. D., Schnürer, A., Smets, B. F., Smid, E. J., et al. (2012) · Microbial Biotechnology · doi:10.1111/1751-7915.12014 · Cited by 19
Isidro, J., Mendes, A. L., Serrano, M., Henriques, A. O., & Oleastro, M. (2017) · InTech eBooks · doi:10.5772/intechopen.69053 · Cited by 24
“warneri, Enterococcus hirae, Lactobacillus reuteri, and three novel species of Anaerostipes, Bacteroidetes and Enterohabdus), and this mix could clear infection by a RT027 strain in mice [40].”
BackgroundInfluentialReviewing the Clostridioides difficile Mouse Model: Insights into Infection Mechanisms
Fachi, J. L., Vinolo, M. A. R., & Colonna, M. (2024) · Microorganisms · doi:10.3390/microorganisms12020273 · Cited by 18
“Likewise, models designed to investigate colonization resistance explore the use of probiotics or microbiota components to enhance the mechanisms of resistance [88–91].”
BackgroundMethodGil, F., & Paredes‐Sabja, D. (2016) · Future Microbiology · doi:10.2217/fmb-2016-0064 · Cited by 14
Invasion of intestinal cells by Staphylococcus warneri, a member of the human gut microbiota
Louail, R., Florin, F., Bernard, S., Michaud, J.-B., Breton, J., Achamrah, N., Tavolacci, M., Coëffier, M., & Ribet, D. (2023) · Gut Pathogens · doi:10.1186/s13099-022-00528-7 · Cited by 19
Fecal microbiota transplantation in treating C lostridium difficile infection
Brown, W. R. (2014) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12160 · Cited by 19
Human microbiome: From the bathroom to the bedside
Malnick, S. D. H., & Melzer, E. (2015) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v6.i3.79 · Cited by 17
The Microbiome in Infectious Diseases
Mitreva, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00008-3 · Cited by 20
Gopalsamy, S. N., Sherman, A. C., Woodworth, M. H., Lutgring, J. D., & Kraft, C. S. (2018) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2017.300 · Cited by 15
“Given determinants of AR may persist in intestinal flora for extended periods of time,(7) we suspect that this patient’s microbiome did not recover before further pressure from broad-spectrum antibiotic use, resulting in the persistence of resistant strains of Klebsiella pneumoniae.(9) In hindsight, the best opportuni…”
BackgroundWolfe, T. J. D., Kates, A., Barko, L., Darien, B. J., & Safdar, N. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00111-19 · Cited by 14
Wang, L., Chen, X., Pollock, N. R., Villafuerte-Gálvez, J., Alonso, C. D., Wang, D., Daugherty, K., Xu, H. J., Yao, J., Chen, Y., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2505269 · Cited by 17
Standards for fecal microbiota transplant: Tools and therapeutic advances
Belotserkovsky, I., Stabryla, L. M., Hunter, M. E., Allegretti, J. R., Callahan, B. J., Carlson, P. E., Daschner, P. J., Goudarzi, M., Guyard, C., Jackson, S. A., et al. (2024) · Biologicals · doi:10.1016/j.biologicals.2024.101758 · Cited by 14
Schenck, L. P., Beck, P. L., & MacDonald, J. A. (2015) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v6.i4.169 · Cited by 22
Gut Microbiota and Human Health: Insights From Ecological Restoration
Orr, M. R., Kocurek, K. M., & Young, D. L. (2018) · The Quarterly Review of Biology · doi:10.1086/698021 · Cited by 14
Multiple sclerosis and the microbiota
Engelenburg, H. J., Lucassen, P. J., Sarafian, J. T., Parker, W., & Laman, J. D. (2022) · Evolution Medicine and Public Health · doi:10.1093/emph/eoac009 · Cited by 16
“Dysbiosis is an imbalance in microbiome composition [88] or a change in normal microbiota [89].”
BackgroundChanyi, R. M., Craven, L. J., Harvey, B., Reid, G., Silverman, M., & Burton, J. P. (2017) · SAGE Open Medicine · doi:10.1177/2050312117708712 · Cited by 15
Horvat, S., Mahnič, A., Breskvar, M., Džeroski, S., & Rupnik, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15434-1 · Cited by 16
Nanki, K., Mizuno, S., Matsuoka, K., Ono, K., Sugimoto, S., Kiyohara, H., Arai, M., Nakashima, M., Takeshita, K., Saigusa, K., et al. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.1.142 · Cited by 16
“ing the diversity of intestinal microbiota and re-establishing colonization resistance.(12) An analysis of fecal microbiota before and after FMT showed that the diversity of microbiota, which was reduced before FMT, was restored after FMT.”
BackgroundEdison, L. K., Kudva, I. T., & Kariyawasam, S. (2023) · Microorganisms · doi:10.3390/microorganisms11102562 · Cited by 11
Clostridium difficile: biological therapies
Martin, J. S. H., Mawer, D. P. C., & Wilcox, M. H. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000433319.82618.8f · Cited by 13
Metabolic Modeling of Clostridium difficile Associated Dysbiosis of the Gut Microbiota
Phalak, P., & Henson, M. A. (2019) · Processes · doi:10.3390/pr7020097 · Cited by 12
“data [12,61–64] and have reduced the glucose concentration and increased AA concentrations for the dysbiosis case consistent with experimental observation [33,110].”
ResultFinding a Sugary Foothold: How Antibiotics Pave the Way for Enteric Pathogens
Stecher, B. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.08.008 · Cited by 13
“Single strains or subdivisions of this bacterial mixture failed, suggesting that microbial diversity is a crucial prerequisite for colonization resistance (Lawley et al., 2012).”
BackgroundJump, R., Kraft, D., Hurless, K. N., Polinkovsky, A., & Donskey, C. J. (2017) · Pathogens and Immunity · doi:10.20411/pai.v2i1.159 · Cited by 14
“Our finding that antibiotic treatment dramatically alters fecal metabolites is consistent with other recent studies [9, 16-21].”
BackgroundResultFecal Microbiota Therapy With a Focus on Clostridium difficile Infection
Brandt, L. J. (2017) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000511 · Cited by 14
“Infusion of a mixture of just six phylogenetically diverse bacteria was able to disrupt intestinal dysbiosis and resolve disease when given tomice with CDI (25).”
BackgroundResultProspects and challenges for intestinal microbiome therapy in pediatric gastrointestinal disorders
Kellermayer, R. (2013) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v4.i4.91 · Cited by 14
Carbon source diversity shapes bacterial interspecies interactions
Ono, H., Tsuru, S., & Furusawa, C. (2025) · The ISME Journal · doi:10.1093/ismejo/wraf224 · Cited by 15
“…species composition and community stability [ 8–14], which in turn plays a key role in essential functions of natural communities, such as global nutrient cycling [15] and food digestion [16], as well as applications of synthetic communities, including bioremediation [17] and bacteriotherapy [18].”
Ji, Y., Luo, K., Zhang, J. M., Ni, P., Xiong, W., Luo, X., Xu, G., Liu, H., & Zeng, Z. (2021) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-021-03382-3 · Cited by 11
“Interestingly, we found the OTUs that were associated with TC and HDL-C produced SCFAs such as Clostridium viride, Butyricicoccus pullicaecorum [51], Lachnospiracea and Ruminococcaceae [52, 53].”
BackgroundThe Contribution of Strains and Hosts to Outcomes in Clostridium difficile Infection
Martin, J. S. H. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2014.11.012 · Cited by 13
Aldrete, S. D. M., Magee, M. J., Friedman‐Moraco, R., Chan, A. W., Banks, G. G., Burd, E. M., & Kraft, C. S. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcp9ewi6qpvtpqy · Cited by 11
Host Immunity to Clostridium difficile PCR Ribotype 017 Strains
Jafari, N. V., Songane, M., Stabler, R. A., Elawad, M., Wren, B. W., Allan, E., & Bajaj‐Elliott, M. (2014) · Infection and Immunity · doi:10.1128/iai.02605-14 · Cited by 11
“In the present study, we characterized host immunity to strain CF5, which was isolated in Belgium in 1995 from an asymptomatic patient (19), and strain M68, which was isolated in 2003 during a large CDI outbreak in Ireland (20).”
BackgroundInfluentialImmune cell type ‘fingerprints’ at the basis of outcome diversity of human infection
Hen‐Avivi, S., & Avraham, R. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.09.012 · Cited by 11
Role of Bile in Infectious Disease: the Gall of 7α-Dehydroxylating Gut Bacteria
Savidge, T., & Sorg, J. A. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2018.12.010 · Cited by 12
“difficile epidemic 027 ribotype as a pathogen capable of directly modulating the host microbiota community to maintain an infective “super-shedder” state (Lawley et al., 2012).”
BackgroundSystematic discovery of probiotics
Forster, S. C., & Lawley, T. D. (2015) · Nature Biotechnology · doi:10.1038/nbt.3111 · Cited by 11
Clostridioides difficile Sporulation
Serrano, M., Martins, D., & Henriques, A. O. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-42108-2_13 · Cited by 10
Otter, J. A. (2015) · Journal of Hospital Infection · doi:10.1016/j.jhin.2015.02.004 · Cited by 12
“ever closer to a ‘synthetic’ FMT, using a carefully configured live bacterial cocktail.(52) However, recurrent CDI is just the first of many potential applications for FMT.”
BackgroundFaecal microbiota transplantation: Key points to consider
Bourlioux, P. (2015) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2015.02.001 · Cited by 10
Li, M., Li, Z., Shu, W., Liu, Y., Wang, Y., & Tang, L. (2016) · Future Microbiology · doi:10.2217/fmb-2015-0002 · Cited by 13
Aronoff, D. M. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu141 · Cited by 10
“Compared with historic, nonepidemic strains, the characteristics of hypervirulent strains include increased transmissibility [10], increased toxin production”
Gonzalez, X., & Irazoqui, J. E. (2024) · Molecular Microbiology · doi:10.1111/mmi.15258 · Cited by 12
“Smaller reference communities (Brand et al., 2015; Kostic et al., 2013; Lawley et al., 2012) and simpler model organisms can be of assistance in understanding such fundamental principles and the evolutionary forces at play.”
Donkersley, P., Rice, A., Graham, R. I., & Wilson, K. (2022) · FEMS Microbiology Ecology · doi:10.1093/femsec/fiac147 · Cited by 11
“…to increased disease susceptibility (Hamdi et al. 2011, Mattila et al. 2012, Maes et al. 2016), through the loss of defensive symbionts (Kaltenpoth and Engl 2014, Flórez et al. 2015) or the abandonment of exploitable microbial niches (Harris et al. 2009, Lawley et al. 2012, Cariveau et al. 2014).”
BackgroundIntestinal Microbiota: First Barrier Against Gut-Affecting Pathogens
Calo‐Mata, P., Ageitos, J. M., Böhme, K., & Barros‐Velázquez, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-28368-5_12 · Cited by 10
Brittnacher, M., Heltshe, S. L., Hayden, H. S., Radey, M. C., Weiss, E. J., Damman, C. J., Zisman, T. L., Suskind, D. L., & Miller, S. I. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158897 · Cited by 9
Tungland, B. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814649-1.00009-0 · Cited by 10
Jouhten, H., Ronkainen, A., Aakko, J., Salminen, S., Mattila, E. J., Arkkila, P., & Satokari, R. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01663 · Cited by 10
Morales, M., Sentchilo, V., Hadadi, N., & van der Meer, J. R. (2021) · Environmental Microbiome · doi:10.1186/s40793-021-00378-x · Cited by 12
“Bioaugmentation in that respect is similar to, for example, application of probiotic bacteria in gut systems [13].”
ResultThe microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre
Hart, A. L., & Hendy, P. (2014) · Proceedings of The Nutrition Society · doi:10.1017/s0029665114001153 · Cited by 10
“In a mouse model of pseudomembranous colitis)((56)) suppression of C.”
BackgroundDietary therapy for clostridium difficile colonization: A case series
Suskind, D. L., Lee, D. Y., Solan, P., Wahbeh, G. T., Hayden, H. S., Brittnacher, M. J., Nuding, M. E., & Miller, S. I. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.02.016 · Cited by 11
Restoration of the gut microbial habitat as a disease therapy
Relman, D. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2475 · Cited by 8
Saliba, R., Mizrahi, A., de Ponfilly, G. P., Monnier, A. L., Zahar, J., & Pilmis, B. (2022) · Antibiotics · doi:10.3390/antibiotics11010070 · Cited by 10
Gut microbiome and neurosurgery: Implications for treatment
Willman, J., Willman, M., Reddy, R., Fusco, A. F., Sriram, S., Mehkri, Y., Charles, J. H., Goeckeritz, J., & Lucke-Wold, B. P. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.139 · Cited by 10
Le transfert de flore digestive : une revue de la littérature
Barbut, F., Collignon, A., Butel, M. J., & Bourlioux, P. (2014) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2014.05.004 · Cited by 12
Isolation and gut microbiota modulation of antibiotic-resistant probiotics from human feces
Tian, P., Xu, B., Sun, H., Li, X., Li, Z., & Wei, P. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.04.002 · Cited by 8
“Antibiotic perturbation of the gut microbiota is one of the major risk factors for dysbacteriosis, diarrhea, and Clostridium difficile colonization (Lawley et al., 2012).”
BackgroundHost—microbial interactions in metabolic diseases: from diet to immunity
Lee, J.-H., & Park, J. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-2087-y · Cited by 7
“To avoid these potential risks of FMT, bacteriotherapy with a defined consortium of symbiotic bacteria was developed to provide colonization resistance against C. difficile (Lawley et al., 2012; Buffie et al., 2015).”
BackgroundMicrobial dysbiosis in systemic lupus erythematosus: a scientometric study
Zhao, M., Wen, X., Liu, R., & Xu, K. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1319654 · Cited by 14
Heimesaat, M. M., Kupz, A., Fischer, A., Nies, D. H., Grass, G., Göbel, U. B., & Bereswill, S. (2013) · European Journal of Microbiology and Immunology · doi:10.1556/eujmi.3.2013.3.11 · Cited by 7
Juhász, J., Kertész‐Farkas, A., Szabó, D., & Pongor, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095511 · Cited by 13
“difficile infections [26–29].”
Pathogens’ Exploitation of the Intestinal Food Web
Tu Anh Pham, N., & Lawley, T. D. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.11.012 · Cited by 8
Khoruts, A. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1465818 · Cited by 8
“difficile in check and allow time for eventual restoration of a diverse microbial ecosystem in the gut from residual microorganisms in the host and continued acquisition of new microorganisms from the environment [16].”
Background
Metadata
- Authors
- Lawley, T. D., Clare, S., Walker, A. W., Stares, M. D., Connor, T. R., Raisen, C., Goulding, D., Rad, R., Schreiber, F., Brandt, C., Deakin, L. J., Pickard, D. J., Duncan, S. H., Flint, H. J., Clark, T. G., Parkhill, J., & Dougan, G.
- Affiliations
- Wellcome Sanger Institute (GB)
- University of Aberdeen (GB)
- London School of Hygiene & Tropical Medicine (GB)
- Corresponding author
- Lawley, Trevor D.
- ORCID
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-25
- Volume
- 8
- Issue
- 10
- Pages
- e1002995
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC3486913
- OpenAlex
- W2171605634
- Cited by
- 540
- References
- 73
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 19 · 2023: 20 · 2022: 24 · 2021: 33 · 2020: 21 · 2019: 37 · 2018: 47 · 2017: 42 · 2016: 71 · 2015: 65 · 2014: 73 · 2013: 61 · 2012: 6
- FWCI
- 45.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Wellcome Trust (076964, 098051)
- Medical Research Council (098051, 93614)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Clostridium difficile infection, gut microbiota, dysbiosis, bacterial therapy, fecal microbiota transplantation, transmissibility, opportunistic pathogens, microbial metabolites, mouse model
- MeSH terms
- Animals, Enterocolitis, Pseudomembranous, Feces, Female, Intestines, Mice, Inbred C3H, Mice, Inbred C57BL, Molecular Sequence Data, Recurrence, Vancomycin, Clostridioides difficile, Probiotics, Drug Resistance, Bacterial, Mice, Microbial Interactions, Microbial Consortia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.